Anbio Biotechnology, a global leader in in vitro diagnostics, has successfully closed its $8 million initial public offering, marking its debut on the Nasdaq Global Market under the ticker symbol “NNNN”. The company plans to utilize the funds to expand its global footprint, accelerate research and development, and advance its mission to transform the diagnostics industry.